ID Biomedical (NASDAQ:IDBE)
Historical Stock Chart
From May 2019 to May 2024
CSC's DVC Enters Clinical Trial for Plague Vaccine Candidate
EL SEGUNDO, Calif., Jan. 10 /PRNewswire-FirstCall/ -- Computer Sciences
Corporation (NYSE:CSC) today announced that DVC LLC, a CSC company, has entered
into a phase 1 clinical trial for its recombinant plague vaccine candidate.
The trial will evaluate the safety, tolerability and immunogenicity of the
vaccine candidate in healthy volunteers between the ages of 18 and 40. Testing
is underway and will continue into 2005 at the University of Kentucky Chandler
Medical Center in Lexington, Ky. Contract research services for the single
center open-label study will be provided by the Covalent Group Inc.
(NASDAQ:CVGR), headquartered in Wayne, Penn.
The plague vaccine candidate is designed to provide protection against the
plague bacterium Yersinia pestis, and was originally identified and developed
by scientists working at the U.S. Army Medical Research Institute of Infectious
Diseases (USAMRIID). Their work involved the identification of suitable
protein antigens and the development of the processes used to assess the
performance of the vaccine. Further development and manufacture of the vaccine
candidate has been achieved by ID Biomedical Corporation (NASDAQ:IDBE),
headquartered in Vancouver, British Columbia, under the DVC prime systems
contract for the Department of Defense Joint Vaccine Acquisition Program
(JVAP).
JVAP's mission is to develop, produce and stockpile FDA-licensed vaccine
products to help protect the warfighter against biological warfare agents. JVAP
consolidates the Department of Defense's efforts for the advanced development,
testing, FDA licensing, production and storage of biological defense vaccines.
USAMRIID, located at Fort Detrick, Md., is the lead medical research laboratory
for the U.S. Biological Defense Research Program, and plays a key role in
national defense and in infectious disease research. The Institute's mission
is to conduct basic and applied research on biological threats resulting in
medical solutions (such as vaccines, drugs and diagnostics) to protect the
warfighter. USAMRIID is a subordinate laboratory of the U.S. Army Medical
Research and Materiel Command.
DVC is a biopharmaceutical company dedicated to the development and licensure
of safe and efficacious biodefense vaccines and therapeutics. DVC is part of
CSC's Enforcement, Security and Intelligence organization, which CSC created in
2002 to support programs enhancing U.S. security.
The safety and efficacy of this product in humans has not been established.
This product is currently under clinical investigation and has not been
licensed by the FDA.
About CSC
Founded in 1959, Computer Sciences Corporation is a leading global information
technology (IT) services company. CSC's mission is to provide customers in
industry and government with solutions crafted to meet their specific
challenges and enable them to profit from the advanced use of technology.
With approximately 91,000 employees, CSC provides innovative solutions for
customers around the world by applying leading technologies and CSC's own
advanced capabilities. These include systems design and integration; IT and
business process outsourcing; applications software development; Web and
application hosting; and management consulting. Headquartered in El Segundo,
Calif., CSC reported revenue of $15.3 billion for the 12 months ended Oct. 1,
2004. For more information, visit the company's Web site at
http://www.csc.com/.
DATASOURCE: Computer Sciences Corporation
CONTACT: April Finnen, Public Relations of DVC LLC, +1-301-607-5004,
; or Rich Venn, Media Relations, Corporate of Computer Sciences
Corporation, +1-310-615-3926,
Web site: http://www.csc.com/